• Understanding better the Impact of Long COVID on Health
    (Credit: pexels)

News & Views

Understanding better the Impact of Long COVID on Health

Feb 28 2022

International researchers from the University of Oxford, the University of Wisconsin School of Medicine and Public Health, Royal Brompton Hospital and Imperial College, London and the University of Zurich, Switzerland have conducted a review on the wide-ranging effects of Long COVID and the associated issues for healthcare providers, specifically highlighting impact on the cardiovascular system.

Spanning each step from a patient’s original coronavirus infection and direct impacts, such as myocardial infarction or inflammatory myocarditis, to the long-term impacts on aspects of wellbeing such as mental health and fatigue, the team concluded that current evidence for the treatment of long COVID is lacking and that our current understanding of pathophysiological mechanisms and treatment options remains limited.

The review also found that the vast inequalities in healthcare provision exposed by COVID-19 continue to be magnified by long COVID and called for global humanitarian efforts to promote and fund equitable access to healthcare, social and welfare support and vaccines across the world.

Dr Betty Raman, of Oxford’s Radcliffe Department of Medicine, said: 'Long COVID is emerging as a major public health issue, which makes it important that we better understand the long-term effects of COVID-19 to improve our treatment of it. This review highlights the wide range of short and long-term health impacts and the mechanisms behind them, which is key to providing treatment and ongoing care.'

Professor Stefan Neubauer, Head of the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, said: 'Long COVID is a huge medical challenge. This review gives a comprehensive update on its effect on the cardiovascular system and will also be important in guiding future research into the condition and for finding new treatments.'

Dr Raman is leading one of the first randomised, double-blind, placebo-controlled studies in the UK. Other trials to date have been open label or non-random assignment of therapy. The team’s work is supported by the NIHR Oxford Biomedical Research Centre, a partnership between Oxford University Hospitals NHS Foundation Trust and the University of Oxford.

The full paper, ‘Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus’, can be read in the European Heart Journal.

More information online


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events